Table 5

Overview of direct oral anticoagulant (DOAC) clinical trials

	Dabigatran	Rivaroxiban	Apixaban	Edoxaban
Trial	RE-LY 2009	ROCKET-AF 2011	ARISTOTLE 2011	ENGAGE AF-TIMI 48 2013
Design	RCT open label	RCT double blind	RCT double blind	RCT double blind
Patients (n)	18,113	14,264	18,201	211,05
Comparator	warfarin	warfarin	warfarin	warfarin
Mean $CHADS_2$	2.1	3.5	2.1	2.8
TTR (%)	65	55	62	65
Follow-up (yr)	2.0	1.9	1.8	2.8
Outcome (risk reduction)*	↓34% stroke/SE ↓7% major bleeding ↓60% ICH	↓12% stroke/SE ↑4% major bleeding ↓33% ICH	↓21% stroke/SE ↓12% major bleeding ↓58% ICH	↓13% stroke/SE ↓20% major bleeding ↓53% ICH
Efficacy	Superior*	Non-inferior	Superior	Non-inferior
Safety	Similar*	Similar	Superior	Superior

TTR = time in therapeutic range SE = systemic embolism ICH = intracranial haemorrhage *high dose